

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Effect of different doses of ketamine on prevention of fentanyl induced coughing during general anesthesia induction

#### Protocol summary

##### Study aim

Determining the effect of different doses of ketamine on the prevention of fentanyl-induced coughing during general anesthesia induction

##### Design

A randomized, triple-blinding clinical trial, with the parallel groups, Phase 3 on 56 patients

##### Settings and conduct

In this randomized three-blind randomized clinical trial, 56 eligible patients referred to Al-Zahra Hospital in Isfahan will be included in the study and randomly divided into 4 groups. Before fentanyl injection, patients are given different doses of ketamine or normal saline. The intervention will be performed in such a way that the patient, the researcher, and the statistical analyst will have no knowledge of the type of intervention and the triple-blind conditions will be established. Then cough severity and hemodynamic parameters of patients will be evaluated and compared between the four groups.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria include patients who are candidates for surgery under general anesthesia using fentanyl, in the age group of 18-65 years, have one or two American Society of Anesthesiologists (ASA), and consent to participate in the study. Exclusion criteria included underlying diseases, history of allergies to the studied drugs, smoking, addiction, Having had upper respiratory infections in the past month, using medications that interfere with the study over the past two weeks.

##### Intervention groups

Intervention group 1: Patients in this group receive ketamine at a dose of 0.15 mg/kg intravenously.  
Intervention group 2: Patients in this group receive ketamine at a dose of 0.20 mg/kg intravenously.  
Intervention group 3: Patients in this group receive ketamine at a dose of 0.25 mg/kg intravenously. Control group: Patients in this group receive normal saline at a dose of 0.20 mg/kg intravenously.

##### Main outcome variables

Cough intensity; Blood pressure; heart rate; oxygen saturation (SPO2)

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20200825048515N55**

Registration date: **2022-06-21, 1401/03/31**

Registration timing: **prospective**

Last update: **2022-06-21, 1401/03/31**

Update count: **0**

##### Registration date

2022-06-21, 1401/03/31

##### Registrant information

##### Name

Asieh Maghami Mehr

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 0000 0000

##### Email address

asimaghami@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-07-22, 1401/04/31

##### Expected recruitment end date

2022-11-22, 1401/09/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Effect of different doses of ketamine on prevention of fentanyl induced coughing during general anesthesia induction

**Public title**

Effect of different doses of ketamine on prevention of fentanyl induced coughing

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Age category 65-18 years Candidate for surgery under general anesthesia using fentanyl American Society of Anesthesiologists (ASA) I or II Satisfaction to participate in the study

**Exclusion criteria:**

Underlying diseases (including heart failure, respiratory, liver, kidney, myocardial ischemic disease, myocardial infarction, hypertension above 140/90 mm Hg, tachycardia (heart rate above 100 beats per minute), depression, asthma, chronic cough) History of allergy to the studied drugs Smoking, addiction Having an upper respiratory infection within the last month Use of drugs such as angiotensin converting enzyme inhibitors (ACEIs), antidepressants (over the past two weeks), and steroids (over the past two weeks) that interfere with the study

**Age**

From **18 years** old to **65 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

**Sample size**

Target sample size: **56**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

In this study, 56 eligible patients are randomly selected. For this, the letter A is written on 14 sheets, the letter B is written on 14 sheets, the letter C is written on 14 sheets, and the letter D is written on 14 sheets and each of them is placed in an envelope. Each patient is then asked to choose one of the envelopes. Depending on the selected envelope, the patient is assigned to one of three groups.

**Blinding (investigator's opinion)**

Triple blinded

**Blinding description**

In order to achieve the triple-blind study, different doses

of Ketamine and placebo will be prepared daily by the operating room nurse (without the researcher's awareness) and placed in the bag and will be labeled A, B, C, and D. And is given daily to the anesthesiologist (researcher). Therefore, the patient, the Investigator, the person recording the clinical and basic information of the patients as well as the statistical analyst will not be aware of the type of intervention.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Isfahan University of Medical Sciences

**Street address**

Street address Isfahan University of Medical Sciences, Hezar Jarib Ave., Azadi Sq

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8179964167

**Approval date**

2022-05-21, 1401/02/31

**Ethics committee reference number**

IR.MUI.MED.REC.1401.079

**Health conditions studied****1****Description of health condition studied**

Candidate patients for surgery under general anesthesia using fentanyl

**ICD-10 code****ICD-10 code description****Primary outcomes****1****Description**

Intensity of cough

**Timepoint**

Every 3 minutes during induction of anesthesia from the time of drug injection until 10 minutes after endotracheal intubation

**Method of measurement**

Fentanyl-Induced Cough Scale (FIC)

## Secondary outcomes

### 1

#### Description

Systolic blood pressure

#### Timepoint

Every 3 minutes during induction of anesthesia from the time of drug injection until 10 minutes after endotracheal intubation

#### Method of measurement

Monitoring device

### 2

#### Description

Diastolic blood pressure

#### Timepoint

Every 3 minutes during induction of anesthesia from the time of drug injection until 10 minutes after endotracheal intubation

#### Method of measurement

Monitoring device

### 3

#### Description

Heart rate

#### Timepoint

Every 3 minutes during induction of anesthesia from the time of drug injection until 10 minutes after endotracheal intubation

#### Method of measurement

Monitoring device

### 4

#### Description

Oxygen saturation (SPO2)

#### Timepoint

Every 3 minutes during induction of anesthesia from the time of drug injection until 10 minutes after endotracheal intubation

#### Method of measurement

Monitoring device

## Intervention groups

### 1

#### Description

Intervention group 1: Patients in this group receive ketamine at a dose of 0.15 mg / kg intravenously within 10 seconds, one minute before fentanyl injection.

#### Category

Treatment - Drugs

### 2

#### Description

Intervention group 2: Patients in this group receive ketamine at a dose of 0.20 mg / kg intravenously within 10 seconds, one minute before fentanyl injection.

#### Category

Treatment - Drugs

### 3

#### Description

Intervention group 3: Patients in this group receive ketamine at a dose of 0.25 mg / kg intravenously within 10 seconds one minute before fentanyl injection.

#### Category

Treatment - Drugs

### 4

#### Description

Control group: Patients in this group receive normal saline at a dose of 0.20 mg / kg intravenously within 10 seconds one minute before fentanyl injection.

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Al-Zahra Hospital

##### Full name of responsible person

Azim Honarmand

##### Street address

Anesthesiology Department, Al-Zahra Hospital, Sefeh Blvd., Tohid Street

##### City

Isfahan

##### Province

Isfahan

##### Postal code

8174675731

##### Phone

+98 31 3620 2020

##### Email

honarmand@med.mui.a.ir

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Esfahan University of Medical Sciences

##### Full name of responsible person

Mansour Siavash Dastjerdi

##### Street address

Vice Chancellor for Research, School of Medicine, Hezar Jarib Street, Isfahan.

##### City

Isfahan

##### Province

Isfahan

##### Postal code

8174673461

**Phone**

+98 31 3668 8597

**Email**

dean@med.mui.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

No

**Title of funding source**

Isfahan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Azim Honarmand

**Position**

Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Anesthesiology Department, Al-Zahra Hospita, Sefeh Blvd., Tohid Street

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174675731

**Phone**

+98 31 3620 2020

**Email**

honarmand@med.mui.a.ir

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Azim Honarmand

**Position**

Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Anesthesiology Department, Al-Zahra Hospita, Sefeh Blvd., Tohid Street

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174675731

**Phone**

+98 31 3620 2020

**Email**

honarmand@med.mui.a.ir

**Person responsible for updating data****Contact****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Nasim Cheshmaviz

**Position**

General Practitioner

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Anesthesiology

**Street address**

Anesthesiology Department, Al-Zahra Hospita, Sefeh Blvd., Tohid Street

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174675731

**Phone**

+98 31 3620 2020

**Fax****Email**

Nasimchesm75@gmail.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

There is no further information

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available